Publication year
2011Source
Nature Reviews. Clinical Oncology, 8, 4, (2011), pp. 233-242ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Radiation Oncology
Medical Oncology
Nuclear Medicine
Journal title
Nature Reviews. Clinical Oncology
Volume
vol. 8
Issue
iss. 4
Page start
p. 233
Page end
p. 242
Subject
ONCOL 3: Translational research; ONCOL 5: Aetiology, screening and detectionAbstract
PET imaging has evolved as an indispensible tool for staging in oncology. Multiple quantitative measurements can be performed, enabling the effects of treatment to be monitored before changes are detectable with the use of conventional imaging modalities. PET tracers are available to visualize and quantify the most important mechanisms of resistance to radiotherapy and chemoradiotherapy. Reproducibility of these tracers depends on the particular tracer and the underlying biology of the process that is being investigated. PET enables clinicians to select patients for intensified treatment on the basis of resistance mechanisms taking place at the molecular level. From translational studies and randomized trials, it has become clear that appropriate patient selection can prevent unnecessary rejection of various treatment options through the observation of individual patients rather than only looking at the results of a large study population.
This item appears in the following Collection(s)
- Academic publications [203856]
- Faculty of Medical Sciences [80326]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.